2006-2010, Site Principal Investigator, An Open-label, Prospective Cohort Study of Antidepressants in Children and Adolescents with Anxiety Disorders, Depressive Disorders, Eating Disorder, or Obsessive-Compulsive Disorder, Duke University

2007-2010, Principal Investigator, A Phase IV, Double-Blind, Placebo-Controlled, Randomized, Flexible-Dose Study of the Safety and Efficacy of Emsam® in Adolescents with Major Depression, Somerset Pharmaceuticals

2008-2011, Principal Investigator, The Evaluation of LAMICTAL as an Add-on Treatment for Bipolar I Disorder in Children and Adolescents, GlaxoSmithKline

2009, Principal Investigator, A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Center, Dose Optimization Study Evaluating the Efficacy and Safety of SPD503 in Combination with Psychostimulants in Children and Adolescents Aged 6-17 with a Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD), Shire Development, Inc